nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylscopolamine bromide—Erectile dysfunction—Sitagliptin—type 2 diabetes mellitus	0.00488	0.00757	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Linagliptin—type 2 diabetes mellitus	0.00483	0.0075	CcSEcCtD
Methylscopolamine bromide—Drowsiness—Glimepiride—type 2 diabetes mellitus	0.00474	0.00735	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Glyburide—type 2 diabetes mellitus	0.00441	0.00685	CcSEcCtD
Methylscopolamine bromide—Drowsiness—Bromocriptine—type 2 diabetes mellitus	0.00428	0.00663	CcSEcCtD
Methylscopolamine bromide—Urticaria—Tolbutamide—type 2 diabetes mellitus	0.00426	0.00661	CcSEcCtD
Methylscopolamine bromide—Palpitations—Repaglinide—type 2 diabetes mellitus	0.00424	0.00658	CcSEcCtD
Methylscopolamine bromide—Constipation—Linagliptin—type 2 diabetes mellitus	0.00413	0.00641	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Tolazamide—type 2 diabetes mellitus	0.00402	0.00624	CcSEcCtD
Methylscopolamine bromide—Constipation—Acarbose—type 2 diabetes mellitus	0.00401	0.00622	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Gliclazide—type 2 diabetes mellitus	0.00396	0.00615	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Repaglinide—type 2 diabetes mellitus	0.00392	0.00607	CcSEcCtD
Methylscopolamine bromide—Tension—Glipizide—type 2 diabetes mellitus	0.0039	0.00604	CcSEcCtD
Methylscopolamine bromide—Urticaria—Chlorpropamide—type 2 diabetes mellitus	0.00388	0.00602	CcSEcCtD
Methylscopolamine bromide—Urticaria—Tolazamide—type 2 diabetes mellitus	0.00388	0.00602	CcSEcCtD
Methylscopolamine bromide—Nervousness—Glipizide—type 2 diabetes mellitus	0.00386	0.00598	CcSEcCtD
Methylscopolamine bromide—Urticaria—Linagliptin—type 2 diabetes mellitus	0.00384	0.00595	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Glipizide—type 2 diabetes mellitus	0.00374	0.0058	CcSEcCtD
Methylscopolamine bromide—Urticaria—Acarbose—type 2 diabetes mellitus	0.00373	0.00578	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Rosiglitazone—type 2 diabetes mellitus	0.0037	0.00574	CcSEcCtD
Methylscopolamine bromide—Tension—Glimepiride—type 2 diabetes mellitus	0.00364	0.00564	CcSEcCtD
Methylscopolamine bromide—Erectile dysfunction—Gliclazide—type 2 diabetes mellitus	0.00363	0.00562	CcSEcCtD
Methylscopolamine bromide—Tension—Sitagliptin—type 2 diabetes mellitus	0.00362	0.00562	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Orlistat—type 2 diabetes mellitus	0.0036	0.00558	CcSEcCtD
Methylscopolamine bromide—Nervousness—Glimepiride—type 2 diabetes mellitus	0.0036	0.00558	CcSEcCtD
Methylscopolamine bromide—Urticaria—Nateglinide—type 2 diabetes mellitus	0.00359	0.00557	CcSEcCtD
Methylscopolamine bromide—Nervousness—Sitagliptin—type 2 diabetes mellitus	0.00359	0.00556	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Linagliptin—type 2 diabetes mellitus	0.00356	0.00552	CcSEcCtD
Methylscopolamine bromide—Nausea—Miglitol—type 2 diabetes mellitus	0.00355	0.0055	CcSEcCtD
Methylscopolamine bromide—Drowsiness—Gliclazide—type 2 diabetes mellitus	0.00351	0.00544	CcSEcCtD
Methylscopolamine bromide—Asthenia—Tolazamide—type 2 diabetes mellitus	0.0035	0.00543	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Glimepiride—type 2 diabetes mellitus	0.00349	0.00541	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Sitagliptin—type 2 diabetes mellitus	0.00348	0.0054	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.00346	0.00536	CcSEcCtD
Methylscopolamine bromide—Headache—Tolbutamide—type 2 diabetes mellitus	0.00336	0.00522	CcSEcCtD
Methylscopolamine bromide—Constipation—Repaglinide—type 2 diabetes mellitus	0.00335	0.00519	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.00333	0.00517	CcSEcCtD
Methylscopolamine bromide—Erectile dysfunction—Valsartan—type 2 diabetes mellitus	0.00333	0.00517	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Metformin—type 2 diabetes mellitus	0.00332	0.00514	CcSEcCtD
Methylscopolamine bromide—Tension—Bromocriptine—type 2 diabetes mellitus	0.00328	0.00509	CcSEcCtD
Methylscopolamine bromide—Palpitations—Glimepiride—type 2 diabetes mellitus	0.00327	0.00508	CcSEcCtD
Methylscopolamine bromide—Confusional state—Glipizide—type 2 diabetes mellitus	0.00327	0.00507	CcSEcCtD
Methylscopolamine bromide—Asthenia—Nateglinide—type 2 diabetes mellitus	0.00325	0.00503	CcSEcCtD
Methylscopolamine bromide—Nervousness—Bromocriptine—type 2 diabetes mellitus	0.00325	0.00503	CcSEcCtD
Methylscopolamine bromide—Dizziness—Tolazamide—type 2 diabetes mellitus	0.00323	0.00501	CcSEcCtD
Methylscopolamine bromide—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.00323	0.00501	CcSEcCtD
Methylscopolamine bromide—Nausea—Tolbutamide—type 2 diabetes mellitus	0.00319	0.00494	CcSEcCtD
Methylscopolamine bromide—Constipation—Rosiglitazone—type 2 diabetes mellitus	0.00317	0.00491	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Bromocriptine—type 2 diabetes mellitus	0.00315	0.00488	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Irbesartan—type 2 diabetes mellitus	0.00313	0.00485	CcSEcCtD
Methylscopolamine bromide—Urticaria—Repaglinide—type 2 diabetes mellitus	0.00311	0.00482	CcSEcCtD
Methylscopolamine bromide—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.00311	0.00482	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Pioglitazone—type 2 diabetes mellitus	0.0031	0.00481	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Glimepiride—type 2 diabetes mellitus	0.00308	0.00478	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Sitagliptin—type 2 diabetes mellitus	0.00308	0.00477	CcSEcCtD
Methylscopolamine bromide—Headache—Tolazamide—type 2 diabetes mellitus	0.00306	0.00474	CcSEcCtD
Methylscopolamine bromide—Headache—Chlorpropamide—type 2 diabetes mellitus	0.00306	0.00474	CcSEcCtD
Methylscopolamine bromide—Confusional state—Glimepiride—type 2 diabetes mellitus	0.00305	0.00473	CcSEcCtD
Methylscopolamine bromide—Headache—Linagliptin—type 2 diabetes mellitus	0.00303	0.0047	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Glimepiride—type 2 diabetes mellitus	0.00302	0.00469	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Sitagliptin—type 2 diabetes mellitus	0.00301	0.00467	CcSEcCtD
Methylscopolamine bromide—Dizziness—Nateglinide—type 2 diabetes mellitus	0.00299	0.00464	CcSEcCtD
Methylscopolamine bromide—Vomiting—Acarbose—type 2 diabetes mellitus	0.00298	0.00463	CcSEcCtD
Methylscopolamine bromide—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.00295	0.00458	CcSEcCtD
Methylscopolamine bromide—Urticaria—Rosiglitazone—type 2 diabetes mellitus	0.00294	0.00456	CcSEcCtD
Methylscopolamine bromide—Drowsiness—Metformin—type 2 diabetes mellitus	0.00294	0.00456	CcSEcCtD
Methylscopolamine bromide—Insomnia—Glipizide—type 2 diabetes mellitus	0.00293	0.00454	CcSEcCtD
Methylscopolamine bromide—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.0029	0.0045	CcSEcCtD
Methylscopolamine bromide—Nausea—Tolazamide—type 2 diabetes mellitus	0.0029	0.0045	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.00289	0.00447	CcSEcCtD
Methylscopolamine bromide—Somnolence—Glipizide—type 2 diabetes mellitus	0.00288	0.00447	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Glyburide—type 2 diabetes mellitus	0.00288	0.00447	CcSEcCtD
Methylscopolamine bromide—Vomiting—Nateglinide—type 2 diabetes mellitus	0.00288	0.00446	CcSEcCtD
Methylscopolamine bromide—Insomnia—Pioglitazone—type 2 diabetes mellitus	0.00281	0.00435	CcSEcCtD
Methylscopolamine bromide—Nausea—Acarbose—type 2 diabetes mellitus	0.00279	0.00432	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Bromocriptine—type 2 diabetes mellitus	0.00278	0.00432	CcSEcCtD
Methylscopolamine bromide—Constipation—Glipizide—type 2 diabetes mellitus	0.00277	0.0043	CcSEcCtD
Methylscopolamine bromide—Confusional state—Bromocriptine—type 2 diabetes mellitus	0.00275	0.00427	CcSEcCtD
Methylscopolamine bromide—Insomnia—Glimepiride—type 2 diabetes mellitus	0.00273	0.00424	CcSEcCtD
Methylscopolamine bromide—Insomnia—Sitagliptin—type 2 diabetes mellitus	0.00273	0.00423	CcSEcCtD
Methylscopolamine bromide—Erectile dysfunction—Losartan—type 2 diabetes mellitus	0.00269	0.00418	CcSEcCtD
Methylscopolamine bromide—Tension—Gliclazide—type 2 diabetes mellitus	0.00269	0.00417	CcSEcCtD
Methylscopolamine bromide—Somnolence—Glimepiride—type 2 diabetes mellitus	0.00269	0.00417	CcSEcCtD
Methylscopolamine bromide—Nausea—Nateglinide—type 2 diabetes mellitus	0.00269	0.00417	CcSEcCtD
Methylscopolamine bromide—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.00268	0.00416	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Glipizide—type 2 diabetes mellitus	0.00267	0.00414	CcSEcCtD
Methylscopolamine bromide—Nervousness—Gliclazide—type 2 diabetes mellitus	0.00266	0.00413	CcSEcCtD
Methylscopolamine bromide—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.00266	0.00413	CcSEcCtD
Methylscopolamine bromide—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.00266	0.00412	CcSEcCtD
Methylscopolamine bromide—Constipation—Sitagliptin—type 2 diabetes mellitus	0.00258	0.004	CcSEcCtD
Methylscopolamine bromide—Urticaria—Glipizide—type 2 diabetes mellitus	0.00257	0.00399	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Pioglitazone—type 2 diabetes mellitus	0.00256	0.00397	CcSEcCtD
Methylscopolamine bromide—Confusional state—Glyburide—type 2 diabetes mellitus	0.00251	0.0039	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Glimepiride—type 2 diabetes mellitus	0.00249	0.00386	CcSEcCtD
Methylscopolamine bromide—Vomiting—Repaglinide—type 2 diabetes mellitus	0.00249	0.00386	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Sitagliptin—type 2 diabetes mellitus	0.00248	0.00385	CcSEcCtD
Methylscopolamine bromide—Insomnia—Bromocriptine—type 2 diabetes mellitus	0.00247	0.00383	CcSEcCtD
Methylscopolamine bromide—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.00247	0.00382	CcSEcCtD
Methylscopolamine bromide—Headache—Repaglinide—type 2 diabetes mellitus	0.00245	0.0038	CcSEcCtD
Methylscopolamine bromide—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00245	0.0038	CcSEcCtD
Methylscopolamine bromide—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.00243	0.00376	CcSEcCtD
Methylscopolamine bromide—Palpitations—Gliclazide—type 2 diabetes mellitus	0.00242	0.00376	CcSEcCtD
Methylscopolamine bromide—Urticaria—Glimepiride—type 2 diabetes mellitus	0.0024	0.00372	CcSEcCtD
Methylscopolamine bromide—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.00239	0.00371	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.00239	0.0037	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Valsartan—type 2 diabetes mellitus	0.00238	0.00368	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Orlistat—type 2 diabetes mellitus	0.00235	0.00364	CcSEcCtD
Methylscopolamine bromide—Constipation—Bromocriptine—type 2 diabetes mellitus	0.00233	0.00362	CcSEcCtD
Methylscopolamine bromide—Nausea—Repaglinide—type 2 diabetes mellitus	0.00233	0.00361	CcSEcCtD
Methylscopolamine bromide—Asthenia—Glipizide—type 2 diabetes mellitus	0.00232	0.0036	CcSEcCtD
Methylscopolamine bromide—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00232	0.0036	CcSEcCtD
Methylscopolamine bromide—Erectile dysfunction—Ramipril—type 2 diabetes mellitus	0.00231	0.00358	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.00229	0.00355	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.00228	0.00354	CcSEcCtD
Methylscopolamine bromide—Tiotropium—CYP3A4—type 2 diabetes mellitus	0.00227	0.43	CrCbGaD
Methylscopolamine bromide—Confusional state—Gliclazide—type 2 diabetes mellitus	0.00226	0.0035	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.00225	0.00349	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.00223	0.00345	CcSEcCtD
Methylscopolamine bromide—Palpitations—Valsartan—type 2 diabetes mellitus	0.00223	0.00345	CcSEcCtD
Methylscopolamine bromide—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.00223	0.00345	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00222	0.00344	CcSEcCtD
Methylscopolamine bromide—Palpitations—Orlistat—type 2 diabetes mellitus	0.0022	0.00341	CcSEcCtD
Methylscopolamine bromide—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.0022	0.00341	CcSEcCtD
Methylscopolamine bromide—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.00219	0.00339	CcSEcCtD
Methylscopolamine bromide—Asthenia—Glimepiride—type 2 diabetes mellitus	0.00217	0.00336	CcSEcCtD
Methylscopolamine bromide—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.00217	0.00336	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Metformin—type 2 diabetes mellitus	0.00216	0.00335	CcSEcCtD
Methylscopolamine bromide—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.00216	0.00335	CcSEcCtD
Methylscopolamine bromide—Dizziness—Glipizide—type 2 diabetes mellitus	0.00214	0.00332	CcSEcCtD
Methylscopolamine bromide—Tension—Irbesartan—type 2 diabetes mellitus	0.00213	0.0033	CcSEcCtD
Methylscopolamine bromide—Nervousness—Irbesartan—type 2 diabetes mellitus	0.0021	0.00326	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Valsartan—type 2 diabetes mellitus	0.0021	0.00325	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Orlistat—type 2 diabetes mellitus	0.00207	0.00322	CcSEcCtD
Methylscopolamine bromide—Vomiting—Glipizide—type 2 diabetes mellitus	0.00206	0.00319	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.00206	0.00319	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.00205	0.00319	CcSEcCtD
Methylscopolamine bromide—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00205	0.00318	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.00204	0.00317	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.00203	0.00315	CcSEcCtD
Methylscopolamine bromide—Headache—Glipizide—type 2 diabetes mellitus	0.00203	0.00315	CcSEcCtD
Methylscopolamine bromide—Palpitations—Metformin—type 2 diabetes mellitus	0.00203	0.00315	CcSEcCtD
Methylscopolamine bromide—Insomnia—Gliclazide—type 2 diabetes mellitus	0.00203	0.00314	CcSEcCtD
Methylscopolamine bromide—Tension—Losartan—type 2 diabetes mellitus	0.002	0.0031	CcSEcCtD
Methylscopolamine bromide—Dizziness—Glimepiride—type 2 diabetes mellitus	0.002	0.0031	CcSEcCtD
Methylscopolamine bromide—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00199	0.00309	CcSEcCtD
Methylscopolamine bromide—Somnolence—Gliclazide—type 2 diabetes mellitus	0.00199	0.00309	CcSEcCtD
Methylscopolamine bromide—Urticaria—Glyburide—type 2 diabetes mellitus	0.00198	0.00307	CcSEcCtD
Methylscopolamine bromide—Nervousness—Losartan—type 2 diabetes mellitus	0.00198	0.00307	CcSEcCtD
Methylscopolamine bromide—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.00196	0.00303	CcSEcCtD
Methylscopolamine bromide—Headache—Pioglitazone—type 2 diabetes mellitus	0.00194	0.00302	CcSEcCtD
Methylscopolamine bromide—Nausea—Glipizide—type 2 diabetes mellitus	0.00192	0.00298	CcSEcCtD
Methylscopolamine bromide—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00192	0.00298	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Losartan—type 2 diabetes mellitus	0.00192	0.00298	CcSEcCtD
Methylscopolamine bromide—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00192	0.00297	CcSEcCtD
Methylscopolamine bromide—Constipation—Gliclazide—type 2 diabetes mellitus	0.00191	0.00297	CcSEcCtD
Methylscopolamine bromide—Headache—Glimepiride—type 2 diabetes mellitus	0.00189	0.00294	CcSEcCtD
Methylscopolamine bromide—Headache—Sitagliptin—type 2 diabetes mellitus	0.00189	0.00293	CcSEcCtD
Methylscopolamine bromide—Insomnia—Valsartan—type 2 diabetes mellitus	0.00186	0.00289	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.00185	0.00286	CcSEcCtD
Methylscopolamine bromide—Insomnia—Orlistat—type 2 diabetes mellitus	0.00184	0.00285	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.00184	0.00285	CcSEcCtD
Methylscopolamine bromide—Somnolence—Valsartan—type 2 diabetes mellitus	0.00183	0.00284	CcSEcCtD
Methylscopolamine bromide—Atropine—CYP1A2—type 2 diabetes mellitus	0.00182	0.344	CrCbGaD
Methylscopolamine bromide—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.0018	0.0028	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.0018	0.0028	CcSEcCtD
Methylscopolamine bromide—Palpitations—Losartan—type 2 diabetes mellitus	0.0018	0.00279	CcSEcCtD
Methylscopolamine bromide—Nausea—Glimepiride—type 2 diabetes mellitus	0.0018	0.00279	CcSEcCtD
Methylscopolamine bromide—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00179	0.00278	CcSEcCtD
Methylscopolamine bromide—Asthenia—Glyburide—type 2 diabetes mellitus	0.00179	0.00277	CcSEcCtD
Methylscopolamine bromide—Urticaria—Gliclazide—type 2 diabetes mellitus	0.00178	0.00276	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.00177	0.00274	CcSEcCtD
Methylscopolamine bromide—Constipation—Valsartan—type 2 diabetes mellitus	0.00176	0.00273	CcSEcCtD
Methylscopolamine bromide—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.00173	0.00269	CcSEcCtD
Methylscopolamine bromide—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.00173	0.00268	CcSEcCtD
Methylscopolamine bromide—Tension—Ramipril—type 2 diabetes mellitus	0.00172	0.00266	CcSEcCtD
Methylscopolamine bromide—Headache—Bromocriptine—type 2 diabetes mellitus	0.00171	0.00265	CcSEcCtD
Methylscopolamine bromide—Nervousness—Ramipril—type 2 diabetes mellitus	0.0017	0.00263	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Losartan—type 2 diabetes mellitus	0.0017	0.00263	CcSEcCtD
Methylscopolamine bromide—Confusional state—Losartan—type 2 diabetes mellitus	0.00168	0.0026	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.00168	0.0026	CcSEcCtD
Methylscopolamine bromide—Somnolence—Metformin—type 2 diabetes mellitus	0.00167	0.00258	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.00166	0.00258	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00165	0.00256	CcSEcCtD
Methylscopolamine bromide—Urticaria—Valsartan—type 2 diabetes mellitus	0.00163	0.00253	CcSEcCtD
Methylscopolamine bromide—Tachycardia—Losartan—type 2 diabetes mellitus	0.00162	0.00252	CcSEcCtD
Methylscopolamine bromide—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00162	0.00251	CcSEcCtD
Methylscopolamine bromide—Urticaria—Orlistat—type 2 diabetes mellitus	0.00161	0.0025	CcSEcCtD
Methylscopolamine bromide—Asthenia—Gliclazide—type 2 diabetes mellitus	0.00161	0.00249	CcSEcCtD
Methylscopolamine bromide—Constipation—Metformin—type 2 diabetes mellitus	0.0016	0.00248	CcSEcCtD
Methylscopolamine bromide—Vomiting—Glyburide—type 2 diabetes mellitus	0.00159	0.00246	CcSEcCtD
Methylscopolamine bromide—Somnolence—Irbesartan—type 2 diabetes mellitus	0.00157	0.00244	CcSEcCtD
Methylscopolamine bromide—Headache—Glyburide—type 2 diabetes mellitus	0.00156	0.00242	CcSEcCtD
Methylscopolamine bromide—Palpitations—Ramipril—type 2 diabetes mellitus	0.00154	0.0024	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.00154	0.00239	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00152	0.00235	CcSEcCtD
Methylscopolamine bromide—Constipation—Irbesartan—type 2 diabetes mellitus	0.00151	0.00234	CcSEcCtD
Methylscopolamine bromide—Insomnia—Losartan—type 2 diabetes mellitus	0.0015	0.00233	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.0015	0.00232	CcSEcCtD
Methylscopolamine bromide—Urticaria—Metformin—type 2 diabetes mellitus	0.00149	0.00231	CcSEcCtD
Methylscopolamine bromide—Nausea—Glyburide—type 2 diabetes mellitus	0.00148	0.0023	CcSEcCtD
Methylscopolamine bromide—Dizziness—Gliclazide—type 2 diabetes mellitus	0.00148	0.0023	CcSEcCtD
Methylscopolamine bromide—Somnolence—Losartan—type 2 diabetes mellitus	0.00148	0.00229	CcSEcCtD
Methylscopolamine bromide—Asthenia—Valsartan—type 2 diabetes mellitus	0.00148	0.00229	CcSEcCtD
Methylscopolamine bromide—Asthenia—Orlistat—type 2 diabetes mellitus	0.00146	0.00226	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.00146	0.00226	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Ramipril—type 2 diabetes mellitus	0.00146	0.00226	CcSEcCtD
Methylscopolamine bromide—Confusional state—Ramipril—type 2 diabetes mellitus	0.00144	0.00223	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.00143	0.00221	CcSEcCtD
Methylscopolamine bromide—Vomiting—Gliclazide—type 2 diabetes mellitus	0.00142	0.00221	CcSEcCtD
Methylscopolamine bromide—Constipation—Losartan—type 2 diabetes mellitus	0.00142	0.00221	CcSEcCtD
Methylscopolamine bromide—Urticaria—Irbesartan—type 2 diabetes mellitus	0.0014	0.00218	CcSEcCtD
Methylscopolamine bromide—Headache—Gliclazide—type 2 diabetes mellitus	0.0014	0.00218	CcSEcCtD
Methylscopolamine bromide—Tachycardia—Ramipril—type 2 diabetes mellitus	0.00139	0.00216	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.00137	0.00213	CcSEcCtD
Methylscopolamine bromide—Dizziness—Valsartan—type 2 diabetes mellitus	0.00136	0.00211	CcSEcCtD
Methylscopolamine bromide—Dizziness—Orlistat—type 2 diabetes mellitus	0.00134	0.00208	CcSEcCtD
Methylscopolamine bromide—Asthenia—Metformin—type 2 diabetes mellitus	0.00134	0.00208	CcSEcCtD
Methylscopolamine bromide—Nausea—Gliclazide—type 2 diabetes mellitus	0.00133	0.00206	CcSEcCtD
Methylscopolamine bromide—Urticaria—Losartan—type 2 diabetes mellitus	0.00132	0.00205	CcSEcCtD
Methylscopolamine bromide—Vomiting—Valsartan—type 2 diabetes mellitus	0.00131	0.00203	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.0013	0.00202	CcSEcCtD
Methylscopolamine bromide—Vomiting—Orlistat—type 2 diabetes mellitus	0.00129	0.002	CcSEcCtD
Methylscopolamine bromide—Insomnia—Ramipril—type 2 diabetes mellitus	0.00129	0.002	CcSEcCtD
Methylscopolamine bromide—Headache—Valsartan—type 2 diabetes mellitus	0.00129	0.002	CcSEcCtD
Methylscopolamine bromide—Headache—Orlistat—type 2 diabetes mellitus	0.00127	0.00197	CcSEcCtD
Methylscopolamine bromide—Asthenia—Irbesartan—type 2 diabetes mellitus	0.00127	0.00197	CcSEcCtD
Methylscopolamine bromide—Somnolence—Ramipril—type 2 diabetes mellitus	0.00127	0.00197	CcSEcCtD
Methylscopolamine bromide—Dizziness—Metformin—type 2 diabetes mellitus	0.00124	0.00192	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.00123	0.0019	CcSEcCtD
Methylscopolamine bromide—Nausea—Valsartan—type 2 diabetes mellitus	0.00122	0.00189	CcSEcCtD
Methylscopolamine bromide—Constipation—Ramipril—type 2 diabetes mellitus	0.00122	0.00189	CcSEcCtD
Methylscopolamine bromide—Nausea—Orlistat—type 2 diabetes mellitus	0.00121	0.00187	CcSEcCtD
Methylscopolamine bromide—Ipratropium bromide—CYP3A4—type 2 diabetes mellitus	0.00119	0.226	CrCbGaD
Methylscopolamine bromide—Asthenia—Losartan—type 2 diabetes mellitus	0.00119	0.00185	CcSEcCtD
Methylscopolamine bromide—Vomiting—Metformin—type 2 diabetes mellitus	0.00119	0.00185	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.00118	0.00182	CcSEcCtD
Methylscopolamine bromide—Headache—Metformin—type 2 diabetes mellitus	0.00117	0.00182	CcSEcCtD
Methylscopolamine bromide—Dizziness—Irbesartan—type 2 diabetes mellitus	0.00117	0.00181	CcSEcCtD
Methylscopolamine bromide—Urticaria—Ramipril—type 2 diabetes mellitus	0.00113	0.00176	CcSEcCtD
Methylscopolamine bromide—Vomiting—Irbesartan—type 2 diabetes mellitus	0.00112	0.00174	CcSEcCtD
Methylscopolamine bromide—Nausea—Metformin—type 2 diabetes mellitus	0.00111	0.00173	CcSEcCtD
Methylscopolamine bromide—Headache—Irbesartan—type 2 diabetes mellitus	0.00111	0.00172	CcSEcCtD
Methylscopolamine bromide—Dizziness—Losartan—type 2 diabetes mellitus	0.0011	0.00171	CcSEcCtD
Methylscopolamine bromide—Vomiting—Losartan—type 2 diabetes mellitus	0.00106	0.00164	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.00105	0.00163	CcSEcCtD
Methylscopolamine bromide—Nausea—Irbesartan—type 2 diabetes mellitus	0.00105	0.00163	CcSEcCtD
Methylscopolamine bromide—Headache—Losartan—type 2 diabetes mellitus	0.00104	0.00162	CcSEcCtD
Methylscopolamine bromide—Asthenia—Ramipril—type 2 diabetes mellitus	0.00102	0.00159	CcSEcCtD
Methylscopolamine bromide—Nausea—Losartan—type 2 diabetes mellitus	0.000988	0.00153	CcSEcCtD
Methylscopolamine bromide—Dizziness—Ramipril—type 2 diabetes mellitus	0.000943	0.00146	CcSEcCtD
Methylscopolamine bromide—Vomiting—Ramipril—type 2 diabetes mellitus	0.000907	0.00141	CcSEcCtD
Methylscopolamine bromide—Headache—Ramipril—type 2 diabetes mellitus	0.000894	0.00139	CcSEcCtD
Methylscopolamine bromide—Nausea—Ramipril—type 2 diabetes mellitus	0.000847	0.00131	CcSEcCtD
Methylscopolamine bromide—CHRM2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	7.23e-05	0.000207	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	7.23e-05	0.000207	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—AGT—type 2 diabetes mellitus	7.22e-05	0.000206	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—AGT—type 2 diabetes mellitus	7.19e-05	0.000206	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	7.12e-05	0.000204	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—AGT—type 2 diabetes mellitus	7.12e-05	0.000204	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—EDNRA—type 2 diabetes mellitus	7.1e-05	0.000203	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	7.1e-05	0.000203	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CYBA—type 2 diabetes mellitus	7.09e-05	0.000203	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—LPL—type 2 diabetes mellitus	7.08e-05	0.000202	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CALM1—type 2 diabetes mellitus	7.07e-05	0.000202	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CYBA—type 2 diabetes mellitus	7.07e-05	0.000202	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	7.03e-05	0.000201	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	7e-05	0.0002	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CYBA—type 2 diabetes mellitus	7e-05	0.0002	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	6.97e-05	0.000199	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	6.95e-05	0.000199	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—PLAT—type 2 diabetes mellitus	6.94e-05	0.000198	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—GHRL—type 2 diabetes mellitus	6.94e-05	0.000198	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—ADCY5—type 2 diabetes mellitus	6.93e-05	0.000198	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—GHRL—type 2 diabetes mellitus	6.92e-05	0.000198	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—PLAT—type 2 diabetes mellitus	6.92e-05	0.000198	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	6.88e-05	0.000197	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CALCA—type 2 diabetes mellitus	6.86e-05	0.000196	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—GHRL—type 2 diabetes mellitus	6.85e-05	0.000196	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—PLAT—type 2 diabetes mellitus	6.85e-05	0.000196	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CALCA—type 2 diabetes mellitus	6.84e-05	0.000195	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CALCA—type 2 diabetes mellitus	6.77e-05	0.000194	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	6.67e-05	0.000191	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	6.65e-05	0.00019	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.64e-05	0.00019	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	6.58e-05	0.000188	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.52e-05	0.000187	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—GNB3—type 2 diabetes mellitus	6.52e-05	0.000187	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.52e-05	0.000186	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—HMOX1—type 2 diabetes mellitus	6.49e-05	0.000186	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	6.46e-05	0.000185	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	6.44e-05	0.000184	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	6.43e-05	0.000184	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	6.41e-05	0.000183	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—CAT—type 2 diabetes mellitus	6.41e-05	0.000183	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	6.38e-05	0.000182	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—C3—type 2 diabetes mellitus	6.37e-05	0.000182	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—GCG—type 2 diabetes mellitus	6.35e-05	0.000182	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	6.35e-05	0.000182	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	6.35e-05	0.000181	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—GCG—type 2 diabetes mellitus	6.33e-05	0.000181	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—PTPN1—type 2 diabetes mellitus	6.33e-05	0.000181	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—GCG—type 2 diabetes mellitus	6.27e-05	0.000179	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	6.27e-05	0.000179	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	6.25e-05	0.000179	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	6.23e-05	0.000178	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	6.23e-05	0.000178	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—APOB—type 2 diabetes mellitus	6.22e-05	0.000178	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	6.21e-05	0.000177	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	6.17e-05	0.000176	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	6.15e-05	0.000176	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.08e-05	0.000174	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.06e-05	0.000173	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—AGT—type 2 diabetes mellitus	6.05e-05	0.000173	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—GSTM1—type 2 diabetes mellitus	6.05e-05	0.000173	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.95e-05	0.00017	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	5.94e-05	0.00017	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—LPL—type 2 diabetes mellitus	5.94e-05	0.00017	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—LEP—type 2 diabetes mellitus	5.93e-05	0.00017	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—APOE—type 2 diabetes mellitus	5.93e-05	0.00017	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CCL2—type 2 diabetes mellitus	5.92e-05	0.000169	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	5.87e-05	0.000168	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.86e-05	0.000168	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.84e-05	0.000167	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.83e-05	0.000167	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.82e-05	0.000166	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—ADCY5—type 2 diabetes mellitus	5.82e-05	0.000166	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.81e-05	0.000166	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—GPX1—type 2 diabetes mellitus	5.8e-05	0.000166	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.76e-05	0.000165	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.76e-05	0.000165	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—CD36—type 2 diabetes mellitus	5.64e-05	0.000161	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.59e-05	0.00016	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—PPP2CA—type 2 diabetes mellitus	5.57e-05	0.000159	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.52e-05	0.000158	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.51e-05	0.000157	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.47e-05	0.000156	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.46e-05	0.000156	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.45e-05	0.000156	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.4e-05	0.000154	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	5.4e-05	0.000154	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.4e-05	0.000154	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—AVP—type 2 diabetes mellitus	5.38e-05	0.000154	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.38e-05	0.000154	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.38e-05	0.000154	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.36e-05	0.000153	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.35e-05	0.000153	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—MTHFR—type 2 diabetes mellitus	5.35e-05	0.000153	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.34e-05	0.000153	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.33e-05	0.000152	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—AVP—type 2 diabetes mellitus	5.33e-05	0.000152	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.31e-05	0.000152	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.3e-05	0.000151	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.29e-05	0.000151	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.28e-05	0.000151	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.28e-05	0.000151	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—PPARA—type 2 diabetes mellitus	5.25e-05	0.00015	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.23e-05	0.000149	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	5.22e-05	0.000149	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—APOB—type 2 diabetes mellitus	5.2e-05	0.000149	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.2e-05	0.000149	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.18e-05	0.000148	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—APOB—type 2 diabetes mellitus	5.15e-05	0.000147	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.14e-05	0.000147	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.13e-05	0.000147	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.12e-05	0.000146	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—AGT—type 2 diabetes mellitus	5.08e-05	0.000145	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.07e-05	0.000145	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—INS—type 2 diabetes mellitus	5.07e-05	0.000145	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—CALM1—type 2 diabetes mellitus	5e-05	0.000143	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.99e-05	0.000143	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	4.98e-05	0.000142	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—APOE—type 2 diabetes mellitus	4.98e-05	0.000142	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—LPL—type 2 diabetes mellitus	4.97e-05	0.000142	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—APOA1—type 2 diabetes mellitus	4.92e-05	0.000141	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—LPL—type 2 diabetes mellitus	4.92e-05	0.000141	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.9e-05	0.00014	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.9e-05	0.00014	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.88e-05	0.000139	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.88e-05	0.000139	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.86e-05	0.000139	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.82e-05	0.000138	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.68e-05	0.000134	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.66e-05	0.000133	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.65e-05	0.000133	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.62e-05	0.000132	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.59e-05	0.000131	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.58e-05	0.000131	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.53e-05	0.00013	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	4.49e-05	0.000128	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—C3—type 2 diabetes mellitus	4.47e-05	0.000128	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.44e-05	0.000127	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.44e-05	0.000127	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—C3—type 2 diabetes mellitus	4.43e-05	0.000127	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—PPARG—type 2 diabetes mellitus	4.34e-05	0.000124	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.28e-05	0.000122	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.27e-05	0.000122	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.27e-05	0.000122	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	4.26e-05	0.000122	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.25e-05	0.000122	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—INS—type 2 diabetes mellitus	4.25e-05	0.000122	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	4.25e-05	0.000121	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.22e-05	0.000121	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.21e-05	0.00012	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	4.21e-05	0.00012	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.19e-05	0.00012	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—RELA—type 2 diabetes mellitus	4.18e-05	0.00012	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.18e-05	0.000119	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	4.18e-05	0.000119	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	4.18e-05	0.000119	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	4.16e-05	0.000119	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	4.16e-05	0.000119	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.14e-05	0.000118	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.13e-05	0.000118	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	4.12e-05	0.000118	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	4.12e-05	0.000118	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.12e-05	0.000118	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.08e-05	0.000117	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.94e-05	0.000113	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.93e-05	0.000112	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	3.9e-05	0.000111	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.89e-05	0.000111	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.81e-05	0.000109	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.77e-05	0.000108	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.75e-05	0.000107	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	3.73e-05	0.000107	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	3.73e-05	0.000107	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.73e-05	0.000107	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.71e-05	0.000106	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.68e-05	0.000105	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	3.57e-05	0.000102	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.57e-05	0.000102	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	3.56e-05	0.000102	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.53e-05	0.000101	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	3.52e-05	0.000101	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.51e-05	0.0001	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.5e-05	0.0001	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.47e-05	9.91e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.46e-05	9.89e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.45e-05	9.87e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.45e-05	9.86e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.44e-05	9.83e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.44e-05	9.83e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.43e-05	9.82e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.42e-05	9.79e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	3.41e-05	9.75e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.41e-05	9.74e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.4e-05	9.73e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.39e-05	9.69e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—SRC—type 2 diabetes mellitus	3.29e-05	9.4e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.28e-05	9.37e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.27e-05	9.34e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.24e-05	9.25e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.2e-05	9.15e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.13e-05	8.94e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.13e-05	8.94e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.12e-05	8.92e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.12e-05	8.92e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.09e-05	8.83e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.09e-05	8.83e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.95e-05	8.42e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.94e-05	8.4e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	2.94e-05	8.39e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	2.91e-05	8.31e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.88e-05	8.24e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.68e-05	7.66e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.67e-05	7.64e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.66e-05	7.59e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.65e-05	7.57e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.65e-05	7.57e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.64e-05	7.54e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.63e-05	7.52e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.62e-05	7.5e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.61e-05	7.45e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.51e-05	7.18e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.5e-05	7.15e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.48e-05	7.1e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.48e-05	7.08e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.48e-05	7.08e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.45e-05	7.01e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.43e-05	6.96e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.43e-05	6.94e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.4e-05	6.87e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.31e-05	6.62e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	2.31e-05	6.6e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	2.28e-05	6.53e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.25e-05	6.44e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.25e-05	6.42e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.23e-05	6.36e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	2.21e-05	6.33e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.07e-05	5.91e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.06e-05	5.9e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.04e-05	5.84e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.04e-05	5.84e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.03e-05	5.8e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.02e-05	5.78e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2e-05	5.72e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	1.71e-05	4.9e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.56e-05	4.46e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.55e-05	4.44e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.54e-05	4.4e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.44e-05	4.11e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.43e-05	4.1e-05	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.42e-05	4.06e-05	CbGpPWpGaD
